Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in asian patients with diabetes

QJM: An International Journal of Medicine

Volumn 109, Issue 2, 2016, Pages 91-95

  Chen, H H ^a,b,c   Lin, C L ^d,e   Yeh, S Y ^c,f   Kao, C H ^d,g  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c Nantou Christian Hospital   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; ANTIDIABETIC AGENT;

ADULT; ARTICLE; ASIAN; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HAZARD RATIO; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SHORT COURSE THERAPY; VACCINATION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; HEALTH INSURANCE; INCIDENCE; PROPORTIONAL HAZARDS MODEL; RANDOMIZATION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TAIWAN; TIME FACTOR;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HERPES ZOSTER; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSURANCE, HEALTH; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOM ALLOCATION; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84960076788     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcv096     Document Type: Article

References (21)

1. http://www.mohw.gov.tw/EN/Ministry/Statistic.aspx?f_list_ no=474&fod_list_no=5007.
2. Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009; 89:612-6.
3. Weitzman D, Shavit O, Stein M, Cohen R, Chodick G, Shalev V. A population based study of the epidemiology of herpes zoster and its complications. J Infect 2013; 67:463-9.
4. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008; 36:226-30.
5. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Eur J Intern Med 2009; 20:S329-39.
6. American Diabetes Association, Standards of Medical Care in Diabetes-2014. Diabetes Care 2014; 37:S14-80.
7. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194-206.
8. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008 Apr 16:CD006739.
9. Cheng TM. Taiwan's National Health Insurance system: high value for the dollar. In: Okma KGH, Crivelli L, ed. Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. New Jersey, World Scientific, 2009, 71-204.
10. Chapman RS, Cross KR, Fleming DM. The incidence of shingles and its implication for vaccination policy. Vaccine 2003; 21:2541-7.
11. Czernichow S, Dupuy A, Flahault A, Chosidow O. Herpes zoster: incidence study among sentinel general pratictioners. Ann Dermatol Venereol 2001; 128:497-501.
12. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplège A, et al. Characteristics of patient with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33:62-9.
13. Geerlings SE, Hoepelman AI. Immune dysfunction in patientswith diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26:259-65.
14. Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospitalbased cohort study. Infection 2011; 39:537-44.
15. Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis 2009; 200:1606-10.
16. Opstelten W, Van Essen GA, Schellevis F, Verheij TJ, Moons KG. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006; 16: 692-5.
17. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008; 4:753-68.
18. Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potentialmolecular target for therapy. Curr Drug Targets Immune EndocrMetabol Disord 2004; 4:11-8.
19. Preller V, Gerber A, Togni M, Wrenger S, Schraven B, Röcken C, et al. CD26/DP IV in T cell activation and autoimmunity. Adv Exp Med Biol 2006; 575:187-93.
20. Klemann C, Schade J, Pabst R, Leitner S, Stiller J, von Hö rsten S, et al. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats agedependently. Clin Exp Immunol 2009; 155:357-65.
21. Price JD, Linder G, Li WP, Zimmermann B, Rother KI, Malek R, et al. Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebocontrolled study. Clin Exp Immunol 2013; 174:120-8.